Biologic for Delayed Graft Function, Diabetic Nephropathy, Kidney Disease, Non Alcoholic Steatohepatitis and Oncology is under clinical development by Unicyte and currently in Phase I for Diabetic Foot Ulcers. According to GlobalData, Phase I drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Biologic for Delayed Graft Function, Diabetic Nephropathy, Kidney Disease, Non Alcoholic Steatohepatitis and Oncology LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Biologic for Delayed Graft Function, Diabetic Nephropathy, Kidney Disease, Non Alcoholic Steatohepatitis and Oncology overview
Biologic is under development for the treatment of delayed graft function, non-alcoholic steatohepatitis, acute kidney injury, chronic kidney disorder, liver cancer, diabetic foot ulcers and renal cancer. The drug candidate comprises of nano-extracellular vesicles (nEV) derived from human liver stem cells (HLSCs).
It was under development for diabetic nephropathy.
Unicyte overview
Unicyte, a subsidiary of Fresenius Medical Care AG & Co KGaA, is a transformative regenerative medicine company that carries out advancing stem cell technologies into a novel class of human therapeutics. The company provides technology platforms such as human liver stem cells (HLSCs), HLSC-derived functional pancreatic islets and nano-extracellular vesicles. Unicyte uses its HLSC technology platform to develop therapeutic solutions for patients with rare and serious chronic liver and kidney diseases. It conducts research into oncology, diabetes and other diseases. The company works in partnership with pharmaceutical and biotechnology companies to develop and commercialize its technology platforms. Unicyte is headquartered in Oberdorf, Switzerland.
For a complete picture of Biologic for Delayed Graft Function, Diabetic Nephropathy, Kidney Disease, Non Alcoholic Steatohepatitis and Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
